Posizioni attive di Jean-Pierre Julien
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
ImStar Therapeutics, Inc.
 ImStar Therapeutics, Inc. BiotechnologyHealth Technology ImStar Therapeutics, Inc. develops therapies for ALS and neurodegenerative disease. The firm's lead drug candidate is IMS-088, a small-molecule compound currently in preclinical development. It is studying compounds directed at a proprietary new therapeutic target for ALS called TANA. The company was founded by Daniel J. Wattier and Jean-Pierre Julien in 2012 and is headquartered in Vancouver, Canada. | Direttore/Membro del Consiglio | 01/01/2012 | - |
| Direttore Tecnico/Scientifico/R&S | 01/01/2012 | - | |
| Fondatore | 01/01/2012 | - |
Storia della carriera di Jean-Pierre Julien
Statistiche
Distribuzione geografica
| Canada | 2 |
Posizioni
| Director/Board Member | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
Settori
| Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 1 |
|---|---|
ImStar Therapeutics, Inc.
ImStar Therapeutics, Inc. BiotechnologyHealth Technology ImStar Therapeutics, Inc. develops therapies for ALS and neurodegenerative disease. The firm's lead drug candidate is IMS-088, a small-molecule compound currently in preclinical development. It is studying compounds directed at a proprietary new therapeutic target for ALS called TANA. The company was founded by Daniel J. Wattier and Jean-Pierre Julien in 2012 and is headquartered in Vancouver, Canada. | Health Technology |
- Borsa valori
- Insiders
- Jean-Pierre Julien
- Esperienza
